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Abstract
Objective
To compare the time from entry into care for HIV infection until combination antiretroviral
therapy (cART) initiation between migrants and non migrants in France, excluding late ac-
cess to care.
Methods
Antiretroviral-naïve HIV-1-infected individuals newly enrolled in the FHDH cohort between
2002–2010, with CD4 cell counts &gt;200/μL and no previous or current AIDS events were
included. In three baseline CD4 cell count strata (200–349, 350-499,500/μL), we exam-
ined the crude time until cART initiation within three years after enrolment according to geo-
graphic origin, and multivariable hazard ratios according to geographic origin, gender and
HIV-transmission group, with adjustment for baseline age, enrolment period, region of care,
plasma viral load, and HBV/HBC coinfection.
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Results
Among 13338 individuals, 9605 (72.1%) were French natives (FRA), 2873 (21.4%) were mi-
grants from sub-Saharan Africa/non-French West Indies (SSA/NFW), and 860 (6.5%) were
migrants from other countries. Kaplan-Meier probabilities of cART initiation were significant-
ly lower in SSA/NFW than in FRA individuals throughout the study period, regardless of the
baseline CD4 stratum. After adjustment, the likelihood of cART initiation was respectively
15% (95%CI, 1–28) and 20% (95%CI, 2–38) lower in SSA/NFWmen than in FRAmen who
had sex with men (MSM) in the 350-499 and500 CD4 strata, while no difference was ob-
served between other migrant groups and FRA MSM.
Conclusion
SSA/NFWmigrant men living in France with CD4 &gt;350/μL at entry into care are more
likely to begin cART later than FRA MSM, despite free access to treatment. Administrative
delays in obtaining healthcare coverage do not appear to be responsible.
Introduction
Although migrants represent 8.4% of the whole population living in France with 5.3 million of
persons [1], heterosexually acquired HIV infection in migrants accounted for 38% of the 6372
new diagnoses of HIV infection in 2012 [2]. Heterosexual female migrants (1466 individuals,
23.0%) and heterosexual male migrants (960 individuals, 15.0%) were the second and third
largest groups among the new diagnoses of HIV infection, after men who have sex with men
(MSM), who accounted for 2648 new diagnoses (42.0%) [2]. Migrants also represented 46% of
new AIDS diagnoses in 2003–2010 [3]. While migrants from sub-Saharan Africa compose only
13% of the immigrant population in France [1], they represent 67.4% of HIV-infected migrants
[2].
Several studies in high-income countries have shown that migrants are at a higher risk of
delayed diagnosis of HIV infection and delayed access to care than other individuals [4,5,6,7].
Furthermore, among people living with HIV engaged in care in France in 2010, fewer migrants
received combination antiretroviral therapy (cART) for more than six months and fewer had
plasma viral loads (pVL) below 50 cp/mL on treatment when compared to non migrant hetero-
sexuals and MSM [8].
Apart from delayed diagnosis of HIV infection, potential differences in healthcare manage-
ment between migrants engaged in care at an early stage of HIV infection and their non mi-
grant counterparts have not yet been studied. Following recommendations to increase HIV
screening [9] and to expand treatment initiation [10,11], our objective was to compare the time
to cART initiation and the types of cART regimens prescribed for migrants and non-migrants
without access to care at an advanced stage of HIV disease in the French Hospital Database
from 2002 to 2010.
Materials and Methods
Individuals
Created in 1989, the FHDH (French Hospital Database on HIV) is a large prospective cohort
study of HIV-infected individuals aged at least 15 years receiving care in one of the 70 French
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participating hospitals; in 2010 it included 50% of HIV-infected persons in care in France [12].
The only enrolment criteria are documented HIV-1 or HIV-2 infection, follow-up in a FHDH
participating center, and written informed consent. Data submitted by the participating centres
to the data coordinating and analysis centre are anonymised, then encrypted. The FHDH was
approved by the institutional ethic committees, Commission Nationale de l’Informatique et
des Libertés (CNIL) on 27 November 1991 (Journal Officiel, 17 January 1992).
The study included antiretroviral treatment-naive HIV-1-infected individuals aged at least
16 years who were newly enrolled in the FHDH between 1 January 2002 and 31 December
2010 with CD4 cell counts above 200/μL and no previous or current AIDS events at enrolment
or within the first three months after enrolment. Individuals were excluded if their first cART
regimen was initiated for pregnancy, if they participated in a double-blind clinical trial of anti-
retroviral therapy during their follow-up in the study, or if they had received single or dual
NRTI therapy before first-line cART. In order to include only persons who really had the op-
portunity to begin treatment, those who were lost to follow-up (n = 1995) or died (n = 28)
within the first six months after FHDH enrolment or who had no immunovirological assess-
ment during the first three months and fewer than two assessments during follow-up (n = 873)
were excluded (Fig. 1).
Statistical Analysis
Migrant status was based on the United Nations definition: “anyone born and having lived out-
side France and now residing in France, whatever their nationality and the duration of stay in
France” [13]. Regions of origin were subdivided as follows: France (FRA) including French
West Indies; sub-Saharan Africa/non-French West Indies (SSA/NFW); and other countries
(OTH, mainly North Africa, America, Asia and Europe). Sub-Saharan Africa and non-French
West Indies were pooled on the basis of their similar proportion of undocumented migrants.
Fig 1. Individuals selection. Abbreviations: ADE, AIDS-defining event; cART, combination antiretroviral
therapy; NRTI, Nucleoside Reverse Transcriptase Inhibitor.
doi:10.1371/journal.pone.0118492.g001
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All antiretroviral combinations that included at least three drugs, or at least two drugs from
ritonavir-boosted protease inhibitors (PI/r), non-nucleoside reverse transcriptase inhibitors
(NNRTI) and integrase inhibitors (II), or ritonavir-boosted PI monotherapy were considered
for the study [10,14]. For descriptive purposes, we distinguished seven groups of cART regi-
mens: regimens with at least two NRTIs plus either an NNRTI, a ritonavir-boosted PI or an
integrase inhibitor which are the three currently recommended cART regimens [15,16], regi-
mens with at least three NRTIs or at least two NRTIs plus one non-boosted PI which are two
previously recommended cART regimens [17], and two other groups with regimens including
at least three drugs or regimens including less than three drugs. These last two groups were in-
dividualized because they included potent drug combinations or strategies under investigation,
such as boosted PI monotherapy or combinations with one ritonavir-boosted PI plus another
potent drug.
Time to first-line cART initiation was calculated from the date of FHDH enrolment to
cART initiation, death, the end of follow-up, 31 December 2011, or three years after the begin-
ning of follow-up, whichever occurred first. As the subjects were treatment-naive at enrolment,
those who started cART on the day of recruitment were artificially given 1 day of follow-up, as
previously described [4].
The Chi2 and Kruskal-Wallis tests were used to compare the characteristics of the individu-
als at enrolment and at cART initiation, and to evaluate differences in first-line cART regimens
across the three regions of origin. Because time to first-line cART initiation varied according to
the baseline CD4 cell count, the crude time to cART initiation was assessed, using Kaplan-
Meier estimates, according to three baseline CD4 cell count strata (200–349, 350–499,500/μL)
and region of origin.
To further explore differences related to geographic origin, gender and HIV transmission
group, a combined 7-category variable was created: MSM originating from France (FRA
MSM), non homosexual men originating from France (FRA non homosexual men), women
originating from France (FRA women), men originating from sub-Saharan Africa/non-French
West Indies (SSA/NFWmen), women originating from sub-Saharan Africa/non-French West
Indies (SSA/NFW women), men originating from other countries (OTH men) and women
originating from other countries (OTH women). Multivariable Hazard Ratios (HRs) for first-
line cART initiation were determined in Cox models according to geographic origin, gender
and HIV transmission group within each baseline CD4 cell count stratum. Age, the enrolment
period, the region of care, baseline pVL, and hepatitis B virus antigen and anti-hepatitis C virus
antibody status were entered in the multivariable model. Regions of care were defined accord-
ing to the epidemiology of HIV infection in France, and comprised the Paris area, southern
France, French West Indies (Martinique, Guadeloupe, French Guyana), and other regions of
metropolitan France plus the Reunion Island [18,19]. Enrolment periods (2002–2005, 2006–
2007 and 2008–2010) were chosen according to the evolution of national and international
cART initiation guidelines [10,14,17]. We also did a sensitivity analysis by using a multivariable
competing risk model taking into account death and censoring occurring prior to cART initia-
tion as a competing risk. All analyses were done with SAS v9.3 software (SAS Institute, Inc,
Cary, NC). A p value<0.05 was considered to denote statistical significance.
Results
Population
Among 16 234 FHDH individuals meeting the inclusion criteria (11 620 originating from
France, 3514 from sub-Saharan Africa/non-French West Indies, 1100 from other countries),
2896 individuals were excluded because of a lack of initial follow-up (Fig. 1). These excluded
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individuals represented 2015/11 620 FRA individuals (17%), 641/3514 SSA/NFW individuals
(18%) and 240/1100 OTH individuals (22%) (p = 0.0008). When comparing these proportions
within each CD4 cell count stratum, this difference was only statistically significant in the
500 CD4 cell count stratum.
A total of 13 338 individuals were thus included in the study, of whom 9605 (72.1%) were
native from FRA, 2873 (21.4%) from SSA/NFW, and 860 (6.5%) from OTH (Table 1). Among
the SSA/NFW individuals, 2565 (89.3%) originated from sub-Saharan Africa and 308 (10.7%)
from non-French West Indies (mainly Haiti: 80.2%). The SSA individuals were similar to the
NFW individuals as regards the sex ratio, HIV transmission group, CD4 cell count, and pVL at
enrolment and at cART initiation (data not shown). Among the OTH individuals, 250 (29.1%)
originated from Central and South America, 225 (26.2%) from Northern Africa, 154 (17.9%)
fromWestern Europe, 97 (11.3%) from Eastern Europe, 89 (10.4%) from Asia, and 45 (5.1%)
from other countries (in the Middle East, North America, Australia and Oceania). MSM ac-
counted for 41.4% of the study population, most of them were from FRA (91.7%) and from
OTH (7.1%). Heterosexuals accounted for 48.0% of the overall study population, of whom
54.2% were from FRA, 40.3% from SSA/NFW and 5.5% from OTH. SSA/NFW individuals
were slightly younger than FRA and OTH individuals (p<0.0001), with respective median
(IQR) ages of 34 (28–41), 36 (30–43) and 35 (29–43) years at FHDH enrolment. The main re-
gion of care was the Paris area, particularly for migrants. Migrants, especially those from SSA/
NFW, had a lower median baseline CD4 cell count than non migrants (p<0.0001).
During a total follow-up of 18 736 person-years, 8543 individuals started first-line cART
and 34 died before cART initiation. Median follow-up from the date of enrolment to the end of
the study period whether or not cART was initiated, was 36 months in each group of individu-
als, whatever the level of the combined variable (geographic origin, gender and HIV transmis-
sion group). Migrants had lower CD4 cell counts at cART initiation than FRA individuals
(p<0.0001). Among individuals who started cART, a first AIDS event occurred before cART
initiation in 145 cases, consisting of tuberculosis in 41 cases (28.3%), Kaposi’s sarcoma in 29
(20.0%), esophageal candidiasis in 17 (11.7%), non-Hodgkin’s lymphoma in 16 (11.0%) and
Pneumocystis jirovecii pneumonia in 14 (9.7%).
Antiretroviral regimens
The first-line cARTs are shown in Table 2. Currently recommended cART regimens, i.e. at
least two NRTIs plus either an NNRTI, a ritonavir-boosted PI or an integrase inhibitor, were
initiated in respectively 4192 (49.1%), 2856 (33.4%) and 185 (2.2%) individuals. Regimens in-
cluding at least two NRTIs plus an NNRTI or a ritonavir-boosted PI were the most prescribed
regimens, whatever the individuals’ origin. Previously recommended cART regimens, i.e. at
least three NRTIs or at least two NRTIs plus one non-boosted PI, were initiated in 945 individ-
uals (11.1%). Other cARTs were initiated slightly more frequently in FRA individuals (4.8%)
than in SSA/NFW (3.0%) and OTH individuals (3.0%).
cART initiation
As shown in Fig. 2, in univariable analyses of each CD4 cell count stratum, time to cART initia-
tion differed significantly across the three individual origins, SSA/NFW individuals starting
cART later than individuals of other origins. For example, in the 350–499 CD4 cell count stra-
tum the one-year probability of cART initiation was 39.0% (37.2–40.8) in FRA individuals,
31.4% (28.3–34.5) in SSA/NFW individuals and 40.1% (34.0–46.2) in OTH individuals.
cART Initiation in Migrants in France
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Table 1. Characteristics of the individuals at enrolment and at cART initiation, N = 13338.
All individuals FRAa SSA/NFWb OTHc p
N = 13338 N = 9605 N = 2873 N = 860
At enrolment
Gender and HIV transmission group
MSM 5515 (41.4) 5058 (52.7) 68 (2.4) 389 (45.2)
Heterosexual men 2795 (21.0) 1599 (16.6) 1008 (35.1) 188 (21.9)
Heterosexual women 3606 (27.0) 1873 (19.5) 1569 (54.6) 164 (19.1)
IDU men 280 (2.1) 227 (2.4) 6 (0.2) 47 (5.5)
IDU women 86 (0.6) 74 (0.8) 3 (0.1) 9 (1.0)
Other men 694 (5.2) 554 (5.7) 90 (3.1) 50 (5.8)
Other women 362 (2.7) 220 (2.3) 129 (4.5) 13 (1.5) <0.0001
Age [years]
<30 3712 (27.8) 2519 (26.2) 935 (32.5) 258 (30.0)
30–39 5124 (38.4) 3669 (38.2) 1140 (39.7) 315 (36.6)
40–49 2948 (22.1) 2221 (23.1) 546 (19.0) 181 (21.1)
50 1554 (11.7) 1196 (12.5) 252 (8.8) 106 (12.3) <0.0001
Enrolment period
2002–2005 6902 (51.8) 4882 (50.8) 1604 (55.8) 416 (48.4)
2006–2007 2927 (21.9) 2100 (21.9) 635 (22.1) 192 (22.3)
2008–2010 3509 (26.3) 2623 (27.3) 634 (22.1) 252 (29.3) <0.0001
Region of care
Paris area 7360 (55.2) 4799 (50.0) 1996 (69.5) 565 (65.7)
Southern France 1193 (8.9) 1023 (10.6) 90 (3.1) 80 (9.3)
Other/Reunion island 4122 (30.9) 3397 (35.4) 577 (20.1) 148 (17.2)
French West Indies 663 (5.0) 386 (4.0) 210 (7.3) 67 (7.8) <0.0001
CD4 cell count [/μL] 431 (316–588) 450 (330–610) 375 (282–508) 435 (313–590) <0.0001
Plasma viral Load [log10 copies/mL] 4.42 (3.78–4.95) 4.47 (3.85–5.00) 4.24 (3.58–4.78) 4.46 (3.89–4.92) <0.0001
Hepatitis B antigen
Negative 9999 (75.0) 6875 (71.6) 2407 (83.8) 717 (83.4)
Positive 835 (6.3) 316 (3.3) 231 (8.0) 36 (4.2)
Unknown 2756 (20.6) 2414 (25.1) 235 (8.2) 107 (12.4) <0.0001
Hepatitis C antibodies
Negative 9966 (74.7) 6767 (70.4) 2533 (88.2) 666 (77.4)
Positive 835 (6.3) 633 (6.6) 103 (3.6) 99 (11.5)
Unknown 2537 (19.0) 2205 (23.0) 237 (8.2) 95 (11.1) <0.0001
At cART initiation N = 8543 N = 6156 N = 1845 N = 542
CD4 cell count [/μL] 309 (246–405 319 (252–419) 284 (229–361) 295 (235–394) <0.0001
Plasma viral Load [log10 copies/mL] 4.65 (3.95–5.14) 4.70 (4.00–5.17) 4.50 (3.80–5.00) 4.77 (4.19–5.12) <0.0001
AIDS status 145 (1.7) 88 (1.4) 45 (2.4) 12 (2.2) 0.0082
Data are counts (proportions) and medians (interquartile range).
a Including French West Indies.
b Including non-French West Indies.
c Including Northern Africa, Asia, Oceania, Australia, North America, Central and South America, Middle East, Western Europe and Eastern Europe.
Abbreviations: FRA, French natives; SSA, sub-Saharan Africa; NFW, non-French West Indies; OTH, Other regions of the world; MSM, Men who have sex
with men; IDU, Injecting drug user, cART, combination antiretroviral therapy;
doi:10.1371/journal.pone.0118492.t001
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Table 2. First-line cART regimens started during follow-up, N = 8543.
All individuals FRA SSA/NFW OTH p
N = 8543 N = 6156 N = 1845 N = 542
Initial cART
2 NRTIs + PI/r 4192 (49.1) 2986 (48.5) 951 (51.6) 255 (47.1)
2 NRTIs + NNRTI 2856 (33.4) 1995 (32.4) 657 (35.6) 204 (37.6)
2 NRTIs + II 185 (2.2) 161 (2.6) 13 (0.7) 11 (2.0)
3 NRTIs 585 (6.9) 436 (7.1) 106 (5.7) 43 (7.9)
2 NRTIs + PI 360 (4.2) 284 (4.6) 63 (3.4) 13 (2.4)
3 other drugsa 128 (1.5) 104 (1.7) 15 (0.8) 9 (1.7)
<3 drugsb 237 (2.7) 190 (3.1) 40 (2.2) 7 (1.3) <0.0001
Data are counts (proportions).
a Mainly PI/r + II or PI/r + NNRTI or 2 PIs/r.
b Mainly PI/r monotherapy or 1 II + 1 PI/r or 1 PI/r + 1 NNRTI.
Abbreviations: FRA, French natives; SSA, sub-Saharan Africa; NFW, non-French West Indies; OTH, Other regions of the world; MSM, Men who have sex
with men; cART, combination antiretroviral therapy; NRTI, Nucleoside Reverse Transcriptase Inhibitor; PI/r, ritonavir-boosted protease inhibitor; NNRTI,
Non-nucleoside Reverse Transcriptase Inhibitor; II, Integrase inhibitor; PI, Protease Inhibitor.
doi:10.1371/journal.pone.0118492.t002
Fig 2. Kaplan-Meier survival estimates of first-line cART initiation by geographic origin and CD4 cell
counts [/μL] at enrolment. Abbreviations: cART, combination antiretroviral therapy; FRA, French natives;
SSA, sub-Saharan Africa; NFW, non-FrenchWest Indies; OTH, Other regions of the world.
doi:10.1371/journal.pone.0118492.g002
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200-349 CD4 cell count stratum
When differences in cART initiation were analyzed by geographic origin, gender and HIV
transmission group (Fig. 3), FRA women and SSA/NFWmen and women had a lower likeli-
hood of cART initiation than FRAMSM in univariable analysis (p = 0.0003). After adjustment,
the only significant difference was that OTH women were 37% (95%CI, 3–81) more likely than
FRAMSM to start cART during the first three years of follow-up.
350-499 CD4 cell count stratum
Univariable analysis gave similar results in this stratum. In adjusted analyses, SSA/NFWmen
were 15% (95%CI, 1–28) less likely than FRAMSM to start cART during their first three years
of follow-up. Median times to cART initiation were 71 weeks for FRAMSM and 113 weeks for
SSA/NFWmen; the respective 25th percentile times to cART initiation were 21 weeks and
38 weeks.
500 CD4 cell count stratum
In univariable analysis, SSA/NFWmen and women were less likely than FRAMSM to start
cART. In multivariable analysis the adjusted likelihood of cART initiation was 20% (95%CI,
2–38) lower in SSA/NFWmen than in FRAMSM, while the difference was no longer signifi-
cant between SSA/NFW women and FRAMSM. Interestingly, although the difference was not
significant, FRA women were 14% (95%CI, -1–29) more likely than FRAMSM to start cART.
Follow-up was too short to estimate median times to cART initiation. The 25th percentile times
Fig 3. Univariate andmultivariate Hazard Ratios (HRs) for cART initiation according to geographic
origin, gender and HIV transmission group in baseline CD4 cell count strata (Coxmodel). * HR
adjusted for age at enrolment, enrolment period, region of care, pVL at enrolment, and hepatitis B antigen
and hepatitis C antibody status; Abbreviations: cART, Combination antiretroviral therapy; FRA, French
natives; SSA, sub-Saharan Africa; NFW, non-FrenchWest Indies; OTH, Other regions of the world; MSM,
Men who have sex with men.
doi:10.1371/journal.pone.0118492.g003
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to cART initiation were 68 weeks for FRA MSM and 109 weeks for SSA/NFWmen. In all three
CD4 cell count strata the results were unaffected when individuals originating from non-
French West Indies were excluded from the SSA/NFW group or when competing risk methods
were used (data not shown).
Discussion
The likelihood of cART initiation was 15% (95%CI, 1–28) lower among migrant men originat-
ing from sub-Saharan Africa or non-French West Indies than among MSM originating from
France when the baseline CD4 cell count was 350–499/μL, and 20% (95%CI, 2–38) lower when
the baseline CD4 cell count was500/μL. No difference between the other migrant groups ver-
sus MSM originating from France was observed in these two strata. In the subpopulation of pa-
tients with baseline CD4 cell counts of 200–349/μL, migrant women originating from other
countries than sub-Saharan Africa or non-French West Indies had a higher adjusted Hazard
Ratio for cART initiation than MSM originating from France.
The FHDH cohort, because of its very large size and extensive follow-up, gave us the oppor-
tunity to assess differences in the timing of cART initiation between migrants and non mi-
grants with early-stage HIV infection in a high income country, according to their geographic
origin, gender, HIV transmission group, and baseline CD4 cell count. In addition, in France,
initial evaluation, first antiretroviral therapy initiation and annual exminations and antiretrovi-
ral renewals are required in an hospital context by physicians expert in HIV infection care [20].
Therefore, this hospital database is a very suitable way to study those differences in cART initi-
ation. One potential limitation of this study could be difference in losses to follow-up between
migrants and non migrants. After adjustment for age, the enrolment period, the region of care,
pVL, hepatitis B antigen and hepatitis C antibody status, all migrant men whatever their geo-
graphic origin and FRA non homosexual men had a higher risk of being lost to follow-up than
MSM originating from France in the CD4 cell count stratum 350–499/μL, and migrant men
from other countries than sub-Saharan Africa/non-French West Indies had a higher risk of
being lost to follow-up than MSM originating from France in the CD4 cell count stratum
500/μL (data not shown). The higher rates of loss to follow-up among the two groups of mi-
grant men could have led to overestimation of the frequency of cART initiation in these groups
in the two highest CD4 cell count strata, and would thus have only diminished the observed
difference in the time to cART initiation. Similar results were obtained when individuals who
were excluded because their follow-up was too short to start treatment, if required by their clin-
ical status, were included in multivariable models (data not shown). We also excluded pregnant
women from the study, and it is possible that some missing data on pregnancy status led to an
overestimation of the Hazard Ratio for first-line cART initiation among women. It is also con-
ceivable that some women with high baseline CD4 cell counts were prescribed first-line cART
when they expressed their intention to become pregnant. This might explain the higher relative
hazard of cART initiation among women migrants from other countries than sub-Saharan Af-
rica/non-French West Indies with baseline CD4 cell counts between 200 and 350/μL, and the
lack of difference in the risk of cART initiation between women originating from sub-Saharan
Africa/non-French West Indies and MSM from France in all three CD4 cell count strata, con-
trasting with the difference observed between migrant men from sub-Saharan Africa/non-
French West Indies and MSM from France.
Despite multivariable analyses taking several potential confounding factors into account,
residual confounders cannot be ruled out. Within each baseline CD4 stratum, counts were
slightly lower in migrants than in MSM born in France, but the results were unaffected
when multivariable analyses included baseline CD4 cell counts within each stratum (data not
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shown). The proportion of individuals enrolled within six months of primary infection was
higher among MSM from France (735 individuals, 14.5%) than among individuals originating
from sub-Saharan Africa/non-French West Indies (38 individuals, 3.2%). This was particularly
apparent in the500 CD4 stratum, with respective proportions of 359/2320 (15.5%) and 13/297
(4.4%); cART was started in respectively 209/359 (3-year Kaplan-Meier probability: 63.8%;
95%CI, 58.9–68.8) and 9/13 (3-year KM probability: 71.2%; 95%CI, 46.5–95.8) of these individ-
uals. When the models were also adjusted for inclusion during versus after the first six months
of primary infection, similar results were obtained showing that primary infection was not the
main driver of the observed difference (data not shown).
Previous studies of the comparative timing of treatment initiation considered either the
overall HIV-infected population whatever the CD4 cell count [4] or the only individuals with a
known date of seroconversion [21]. They showed no major differences in the timing of cART
initiation between individuals originating from sub-Saharan Africa and non migrants after ad-
justment for the CD4 cell count at HIV diagnosis. We excluded individuals with CD4 cell
count below 200/μL and/or a current or previous AIDS event at HIV diagnosis, as these indi-
viduals are likely to start cART rapidly in France, irrespective of their administrative status, fi-
nancial resources and healthcare coverage. Indeed, antiretroviral therapy is provided free of
charge in France for all individuals requiring urgent treatment, and for all other individuals
able to demonstrate they have been living in France for more than 3 months [22]. Given the
large proportion of patients presenting with low CD4 cell counts, excluding these patients from
our analyses explains the difference observed between our results and results found by others
[4].
One important finding in our study is the lower likelihood of cART initiation among men
from sub-Saharan Africa/non-FrenchWest Indies who had high CD4 cell counts (above 350/μL)
at FHDH enrolment, an observation probably reflecting the respect of treatment initiation
guidelines [10,11] for all individuals with CD4 cell counts between 200 and 350/μL, regardless
of their geographic origin, gender and HIV transmission group [23,24], whereas geographic or-
igin may play a role in the decision to treat persons with higher counts. In France, in addition
to later HIV screening [8,25,26] and later access to care [6], migrant men from sub-Saharan Af-
rica and non-FrenchWest Indies also start cART later than MSM from France when diagnosed
at an early stage of HIV infection, despite free universal healthcare. In the 350–499/μL CD4
cell count stratum, the median time to cART initiation was 71 weeks for MSM originating
from France and 113 weeks for men originating from sub-Saharan Africa/non-French West In-
dies, and the respective 25th percentile times to cART initiation were 21 and 38 weeks. In the
500/μL CD4 cell count stratum, the 25th percentile times to cART initiation were 68 weeks
for MSM originating from France and 109 weeks for men originating from sub-Saharan Af-
rica/non-French West Indies. These times are longer than the three to four months needed to
obtain healthcare coverage after entry into care.
Proportions of currently recommended cART (ie at least 2 NRTIs plus either a ritonavir-
boosted PI, a NNRTI or an integrase inhibitor) were higher in migrants (87.6%) than in non
migrants (83.5%) unlike in other study [4]. Investigational strategies are more often prescribed
in people originating from France, and it is conceivable that MSM from France, more volunteer
to HIV screening than migrants from sub-Saharan Africa and being more aware of HIV/AIDS
care and treatments [26], may ask for newer antiretroviral combinations which could differ
with the current recommended treatments [22].
The later cART initiation in male migrants originating from sub-Saharan Africa/non-
French West Indies with relatively high CD4 cell counts requires further studies to determine
the respective roles of patients and their physicians’ decisions. It is possible, for instance, that
physicians delay cART initiation because they anticipate poor adherence to treatment related
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to socio-economic deprivation, with a risk of lower efficacy and selection of resistant viruses.
Alternatively, migrants may hesitate to start treatment because of a lack of knowledge of HIV
infection, misconceptions of the HIV transmission risks, or fear of stigmatization, due to socio-
economic, cultural or language barriers [27]. A better understanding of the factors underlying
the delayed cART initiation in these populations could help to design appropriate interven-
tions, in the context of new French national guidelines recommending antiretroviral therapy
for all HIV-infected individuals regardless of their CD4 cell count, and promoting “combined
prevention” based on behavioral measures, testing strategies and antiretroviral therapy, i.e.
treatment as prevention [11,28].
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